retatrutide triple agonist obesity trial hormone receptor for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a Retatrutide (LY3437943), a Novel GIP/GLP-1/Glucagon
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16




























